1. Livingston, P.O. 1998. The case for melanoma vaccines that induce antibodies. In Molecular Diagnosis Prevention and Treatment of Melanoma, J.M. Kirkwood, ed. Marcel Dekker, Inc: 139–157.
2. Zhang, H., S. Zhang, N.K. Cheung, G. Ragupathi, and P.O. Livingston. 1998. Antibodies can eradicate cancer micrometastases. Cancer Res 58:2844–2849.
3. Jones, P.C., L.L. Sze, P.Y. Liu, D.L. Morton, and R.F. Irie. 1981. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. JNCI 66:249–254.
4. Livingston, P.O., G. Ritter, P. Srivastava, M. Padavan, M.J. Calves, H.F. Oettgen, and L.J. Old. 1989. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49:7045–7050.
5. Livingston, P.O., G.Y.C. Wong, S. Adluri, Y. Tao, M. Padavan, R. Parente, C. Hanlon, F. Helling, G. Ritter, H.F. Oettgen, and L.J. Old. 1994. Improved survival in AJCC stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036–1044.